Company news
Percheron Therapeutics Limited (ASX:PER) news
Percheron Therapeutics Limited news releases on 6ix. Latest, Aug 31, 2026: Percheron raises $2.3m to fully fund clinical trial in AML
Press releases & updates
Percheron raises $2.3m to fully fund clinical trial in AML
August 31, 2026
Vanderbilt Health to conduct clinical trial of HMBD-002
August 27, 2026
Percheron Therapeutics Announces CEO Succession
August 9, 2026
Results of Entitlement Offer
April 14, 2026
Prospectus - Non-renounceable Entitlement Offer
March 15, 2026
Non-renounceable Entitlement Offer
March 15, 2026
Half Yearly Report and Accounts
February 26, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Quarterly Activities Report and Appendix 4C
October 30, 2025
Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
September 11, 2025
Appendix 4E and Annual Report
August 28, 2025
Percheron licenses HMBD-002 from Hummingbird Bioscience
June 26, 2025
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
June 25, 2025
Trading Halt
June 24, 2025
Response to ASX Query
March 6, 2025
Letter From The Chair and Half Year Accounts
February 19, 2025
Topline Six-Month Results From Phase IIb Study of Avicursen
December 17, 2024
Clinical Trial Update
December 1, 2024
Results of Share Purchase Plan
November 12, 2024
Percheron to launch Share Purchase Plan
October 22, 2024
$13.0 million Institutional Placement
October 17, 2024
Completion of avicursen (ATL1102) toxicology study
September 29, 2024
Phase IIb study of ATL1102 in DMD completes recruitment
May 28, 2024
Receipt of R&D Tax incentive payment
February 11, 2024
Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
September 25, 2023
Antisense Share Purchase Plan (SPP) Raises $3.26 Million
August 20, 2023
Share Purchase Plan (SPP) Offer Booklet
July 28, 2023
Positive new DMD Combination Therapy Data in mdx mice
July 25, 2023
Intention to launch Share Purchase Plan
July 20, 2023
Quarterly Activities Report
July 20, 2023
Institutional Placement and proposed Share Purchase Plan SPP
July 18, 2023
MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
June 27, 2023
First Patient Dosed in ATL1102 Phase IIb DMD Trial
June 7, 2023
Chief Executive Officer and Managing Director Appointment
May 7, 2023
PIIb DMD trial approved in Bulgaria- UK, Australia advancing
April 26, 2023
Dosing commenced in the ATL1102 toxicology study
March 13, 2023
Receipt of R&D Tax Incentive Payment
February 22, 2023
First approval for ATL1102 Phase IIb DMD clinical trial
February 13, 2023
Limb Girdle Muscular Dystrophy R2 animal study commenced
February 12, 2023
Positive outcomes in DMD combination therapy animal study
January 31, 2023
Antisense Therapeutics CEO announces retirement
November 14, 2022
ATL1102 tox study to support clinical program in the US
November 13, 2022
Dosing commenced in DMD combination therapy study
September 11, 2022
ATL1102 Revised Clinical Development Plans Presentation
September 6, 2022
ATL1102 Revised Plans accelerate reporting of unblinded data
September 6, 2022
Appendix 4E and Full Year Statutory Accounts
August 31, 2022
Long COVID study identifies diagnostic & therapeutic targets
August 19, 2022
Reinstatement to Official Quotation
August 19, 2022
Long Covid-19 Collaboration Outcomes Presentation
August 19, 2022
Voluntary Suspension
August 17, 2022